Investigational drug · Phase 2
MR-VAC
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diarrhoea.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
6
Any phase or sponsor naming "MR-VAC"
First trial start
2021
Oct 6, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MR-VAC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diarrhoea
Largest trials
Live from ClinicalTrials.gov: studies naming "MR-VAC" as an intervention, largest first.
GlaxoSmithKlineGSK (GSK)
NCT02699099 · 699 participants · Start May 10, 2017 · Primary completion Mar 14, 2018
Drug: Candidate Plasmodium falciparum malaria vaccine; MR-Vac and 1 more · For: Malaria; Malaria Vaccines
Sites: Kintampo, Ghana; Kumasi, Ghana
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05073003 · 551 participants · Start Oct 6, 2021 · Primary completion Jun 24, 2025
Drug: AltSonflex1-2-3 High Dose; AltSonflex1-2-3 Medium Dose and 4 more · For: Diarrhoea
Sites: Ghent, Belgium; Kericho, Kenya
- A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT07466316 · 342 participants (planned) · Start Jul 14, 2026 · Primary completion Jun 30, 2034
Drug: Cyclophosphamide; Dactinomycin and 3 more · For: Rhabdomyosarcoma
Sites: Birmingham, Alabama; Mobile, Alabama; Little Rock, Arkansas · 138 sites in all
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06663436 · 200 participants · Start Nov 13, 2024 · Primary completion Oct 21, 2025
Drug: altSonflex1-2-3 Dose A; altSonflex1-2-3 Dose B and 3 more · For: Diarrhoea
Sites: Kericho, Kenya
- A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06213506 · 180 participants · Start Jan 15, 2024 · Primary completion Aug 6, 2026
Drug: iNTS-GMMA Dose C; iNTS-GMMA Dose B and 5 more · For: Salmonella Infections
Sites: Kumasi, Ghana
- A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaPivotal-lookingActive, not recruiting
Children's Oncology GroupResearch network
NCT04994132 · 113 participants · Start Sep 14, 2021 · Primary completion Jun 30, 2026
Drug: Cyclophosphamide; Dactinomycin and 2 more · For: Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma and 5 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 250 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.
Thuluva S, Gunneri S, Turaga K, et al. · Contemp Clin Trials Commun 2023
- Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial.
Baker B, Bermingham IM, Leelasena I, et al. · Vaccines (Basel) 2023
- Immunogenicity and safety of Mebellaࡊ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study.
Krishna Susarla S, Jahagirdar R, Ghosh Uttam K, et al. · Vaccine 2023
Also in development for Diarrhoea
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- AltSonflex1-2-3Phase 23 trials
GSK · Diarrhoea
- TYPHIBEVPhase 23 trials
GSK · Diarrhoea, Salmonella Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.